Investors were surely discovering drug discovery company AbCellera Biologics (ABCL 4.39%) as the trading week kicked off on Monday. On encouraging news in an important North American jurisdiction, those folks bid the biotech's stock up by almost 6% on the day. That was a far higher jump than the 0.4% increase of the benchmark S&P 500 index.
Moving forward with dermatitis treatment
Friday afternoon, AbCellera announced that it had received a no objection letter (NOL) from Health Canada, that country's healthcare regulatory agency, regarding one of its early-stage investigational drugs. The NOL covers the company's clinical trial application (CTA) for ABCL575, a treatment that targets moderate to severe atopic dermatitis (a chronic skin condition also known as atopic eczema).
Image source: Getty Images.
Receipt of an NOL is an important step in advancing a clinical program for companies like AbCellera, hence the positive market reaction to the news.
AbCellera said in its press release revealing the NOL that it anticipates launching a phase 1 clinical study of ABCL575 in the third calendar quarter of this year. It will be administered by injection to trial participants.
One of very many
AbCellera is a busy company, boasting over 20 investigational programs that sprawl across a number of indications. To some degree, this latest news item is something of a drop in the bucket, particularly since AbCellera's native Canadian market is significantly smaller than that of the U.S.
Regardless, any good news coming from a regulator is a positive for a biotech, so investors were right to cheer Health Canada's move.
